



ASX Announcement

IMRICOR ADDS FOURTEENTH SITE AND FIRST IN GREECE

3 January 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the **Henry Dunant Hospital Centre in Athens, Greece** (<https://www.dunant.gr/en/>) is the latest institution to adopt Imricor's iCMR ablation solutions.

The Company signed an Equipment and Disposable Pricing Agreement (Agreement) on 31 December, 2021 with the Henry Dunant Hospital Centre, one of the largest and most technologically advanced hospital centres in Southeast Europe, making it the fourteenth Imricor site in Europe and the first in Greece. The Company will outfit an existing MR facility for iCMR procedures, which are expected to begin in the first quarter of 2022 under the direction of electrophysiologist Professor George Andrikopoulos.

Imricor's Chair and CEO, Steve Wedan, said: "We are very excited to work with Professor Andrikopoulos and his world-class team at Henry Dunant to bring iCMR cardiac ablations, for the first time, to patients in Greece.

"More broadly, we are very pleased to see the acceleration in our rate of site adoption, **adding four sites in the last quarter of 2021**, and we remain focused on growing our installed base across Europe, as we enter 2022 with great enthusiasm."

The Agreement sets pricing for the one-time purchase of capital equipment needed to outfit an iCMR lab at the Henry Dunant Hospital Centre, including Imricor's Advantage-MR EP Recorder/Stimulator as well as other third-party equipment sold by Imricor. The Agreement also sets pricing for Imricor's single-use consumable devices, such as the Vision-MR Ablation Catheter. The Agreement was effective upon signing and has a term of 3 years from 31 December 2021. Either party may terminate the Agreement at any time.

The Agreement is significant as it is a key strategic goal of Imricor to grow the number of sites performing realtime iCMR cardiac ablation procedures in Europe. Planning is underway for procedures to commence in the first quarter of 2022.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.



Further Information

Investors:

Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Investors & Australian Media:

Brett Ward
Senior Advisor, Cato & Clive
Email: brett@catoandclive.com
Mobile: +61 437 994 451

Rest of World Media:

Nick Twohy
Vice President of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407

Investors (Australia):

Aisha Jabeen
Advisor, Cato & Clive
Email: aisha@catoandclive.com
Phone: +61 430 563 964

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.